biostudies-literatureUnknown44(2)Xiyu LI<h4>Objective</h4>To investigate the effectiveness and safety of Jiawei Xiaoyao pill (，JXP) in the treatment of symptoms associated with premenstrual syndrome (PMS).<h4>Methods</h4>A total of 144 regularly menstruating women with PMS were recruited at 8 sites in China from August 2017 to December 2018, and randomized to receive either a JXP or a matching placebo (12 g/d, 6 g twice a day) for 3 menstrual cycles. The primary indicator was the reduced Daily Record of Severity of Problems (DRSP) scores in the luteal phase after 3 months of treatment. The safety outcomes included clinical adverse events (AEs), adverse reactions (ARs), changes in vital signs, and laboratory tests.<h4>Results</h4>JXP surpassed the placebo in reducing DRSP scores (psychological/somatic dysfunction) in the luteal pJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan373-380https://www.ebi.ac.uk/biostudies/studies/S-EPMC10927397biostudies-literatureEffectiveness and safety of Jiawei Xiaoyao pill in the treatment of premenstrual syndrome (liver depression, spleen deficiency, and blood-heat syndrome): a multi-center, randomized, placebo-controlled trial.PMC10927397Xiyu LIJunping YUJian SQuanfang NYun STing ZGuifen LIZhuangjin ZYi XULifen LYanhong YfalseEffectiveness and safety of Jiawei Xiaoyao pill in the treatment of premenstrual syndrome (liver depression, spleen deficiency, and blood-heat syndrome): a multi-center, randomized, placebo-controlled trial.<h4>Objective</h4>To investigate the effectiveness and safety of Jiawei Xiaoyao pill (，JXP) in the treatment of symptoms associated with premenstrual syndrome (PMS).<h4>Methods</h4>A total of 144 regularly menstruating women with PMS were recruited at 8 sites in China from August 2017 to December 2018, and randomized to receive either a JXP or a matching placebo (12 g/d, 6 g twice a day) for 3 menstrual cycles. The primary indicator was the reduced Daily Record of Severity of Problems (DRSP) scores in the luteal phase after 3 months of treatment. The safety outcomes included clinical adverse events (AEs), adverse reactions (ARs), changes in vital signs, and laboratory tests.<h4>Results</h4>JXP surpassed the placebo in reducing DRSP scores (psychological/somatic dysfunction) in the luteal p2024-01-01T00:00:00Z2024 Apr2026-03-18T14:14:21.892Z2025-08-24T03:05:15.581ZS-EPMC109273973850454310.19852/j.cnki.jtcm.20231110.003